Why Does MELAS Syndrome Cause Diabetes? (MIDD Explained)
At a Glance
MELAS syndrome causes a unique type of diabetes because the pancreas lacks the cellular energy needed to release insulin. It is not caused by diet or weight. It requires specialized treatments, as common medications like Metformin can cause dangerous lactic acidosis in MELAS patients.
In this answer
4 sections
Many people diagnosed with MELAS syndrome are surprised to develop diabetes, especially if they are young, physically active, or not overweight. If you have MELAS, your diabetes was not caused by your diet, your weight, or your lifestyle. Instead, it developed because your pancreas does not have enough cellular energy to do its job. This type of diabetes is a direct result of the mitochondrial dysfunction that causes MELAS, and it is fundamentally different from the more common forms of diabetes you may have heard about.
How MELAS Causes Diabetes
The most common genetic mutation that causes MELAS (the m.3243A>G mutation) is also the primary cause of a specific type of diabetes known as Maternally Inherited Diabetes and Deafness (MIDD) [1].
To understand why this happens, it helps to look at how your body normally processes sugar. In a healthy body, specialized cells in the pancreas (called beta cells) detect sugar in your bloodstream and release insulin to help your body use that sugar for energy.
Producing and releasing insulin requires a massive amount of cellular energy [2]. Beta cells rely heavily on mitochondria—the power plants of the cell—to generate this energy in the form of a molecule called ATP [3]. In MELAS syndrome, the mitochondria cannot produce enough ATP [1]. When your beta cells experience this energy shortage, they simply do not have the power to release insulin into your bloodstream [4][5]. Over time, these energy-starved beta cells may become damaged and fail entirely [6].
Why This Isn’t Typical Type 2 Diabetes
Typical Type 2 diabetes is strongly linked to weight and lifestyle because it is driven by insulin resistance—meaning the body makes insulin but cannot use it properly due to excess body fat or other metabolic factors.
MELAS-related diabetes is driven by a lack of energy, not a lack of effort on your part [7]. People with this type of diabetes are very often not overweight because the root cause is a genetic energy deficiency, rather than obesity-related metabolic problems [8].
It is also distinct from Type 1 diabetes, which is an autoimmune disease where the body’s immune system attacks the pancreas [9]. Your diabetes is instead part of the broader pattern of mitochondrial multisystem involvement seen in MELAS, where organs that require the most energy (like the brain, muscles, and pancreas) are the first to struggle [10][11].
A note on diet: While your diet and weight did not cause this condition, maintaining a healthy lifestyle and managing your carbohydrate intake remains incredibly important. Proper nutritional management is still necessary to control your blood sugar spikes and protect your overall health.
The Role of Mutation Load
The severity of MELAS symptoms often depends on a concept called heteroplasmy, which is the ratio of healthy mitochondria to mutated mitochondria in your cells [12]. Research shows that people with a higher percentage of the m.3243A>G mutation tend to develop diabetes at a younger age and may experience a more severe progression of the disease [13][14]. Because the mutation load can vary from organ to organ, it is common for the pancreas to be heavily affected even if other organs are relatively stable [15].
Important Treatment Considerations
Because MELAS-related diabetes is fundamentally different from Type 1 or Type 2 diabetes, it requires a specialized approach to care:
- Medication cautions: You must ensure all your specialists are aware of your mitochondrial diagnosis, as some common medications can negatively affect mitochondrial function. For example, doctors must be careful when prescribing common diabetes medications. Metformin is frequently prescribed as a first-line treatment for typical diabetes, but it is often avoided in patients with MELAS due to a risk of worsening lactic acidosis (a dangerous buildup of lactic acid in the blood) [16].
- Early-stage medications and insulin: Because the pancreas struggles to make insulin, many patients with MELAS-related diabetes will eventually require insulin injections to manage their blood sugar [17]. However, before insulin becomes necessary, some doctors prescribe newer diabetes medications, such as GLP-1 receptor agonists or SGLT2 inhibitors, which have shown promising results in some people with mitochondrial diabetes [18][19][20].
- Monitoring for other symptoms: Because the diabetes is tied to the m.3243A>G mutation, your care team should also monitor you for other connected symptoms, such as hearing loss, muscle weakness, or specific vision changes (macular pattern dystrophy) [17][21].
Common questions in this guide
Why did I develop diabetes with MELAS syndrome if I am healthy and not overweight?
Is MELAS-related diabetes the same as Type 1 or Type 2 diabetes?
Are standard diabetes medications safe for people with MELAS syndrome?
Will I need insulin to treat my MELAS-related diabetes?
What other symptoms should I watch for with MELAS-related diabetes?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given that my diabetes is caused by mitochondrial dysfunction, what are the safe alternatives to Metformin for managing my blood sugar?
- 2.Should I see an endocrinologist who specializes in mitochondrial disease, or is there a way to coordinate my current care team better?
- 3.Should we test my C-peptide levels to see how much insulin my pancreas is still able to produce?
- 4.Would a Continuous Glucose Monitor (CGM) be right for me to help track my energy levels and blood sugar throughout the day?
- 5.How frequently should I be screened by an audiologist or an eye doctor for hearing loss and macular pattern dystrophy (e.g., annually)?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (21)
- 1
[A case of recurrent cerebellitis leading to the diagnosis of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)].
Ito Y, Ochi C, Yamanishi Y, et al.
Rinsho shinkeigaku = Clinical neurology 2025; (65(8)):601-606 doi:10.5692/clinicalneurol.cn-002117.
PMID: 40707189 - 2
One mutation, three phenotypes: novel metabolic insights on MELAS, MIDD and myopathy caused by the m.3243A > G mutation.
Esterhuizen K, Lindeque JZ, Mason S, et al.
Metabolomics : Official journal of the Metabolomic Society 2021; (17(1)):10 doi:10.1007/s11306-020-01769-w.
PMID: 33438095 - 3
Mitochondrial DNA A3243G variant-associated retinopathy: Current perspectives and clinical implications.
Coussa RG, Parikh S, Traboulsi EI
Survey of ophthalmology 2021; (66(5)):838-855 doi:10.1016/j.survophthal.2021.02.008.
PMID: 33610586 - 4
Exposure to inorganic arsenic and its methylated metabolites alters metabolomics profiles in INS-1 832/13 insulinoma cells and isolated pancreatic islets.
Li YY, Douillet C, Huang M, et al.
Archives of toxicology 2020; (94(6)):1955-1972 doi:10.1007/s00204-020-02729-y.
PMID: 32277266 - 5
Metabolic cycles and signals for insulin secretion.
Merrins MJ, Corkey BE, Kibbey RG, Prentki M
Cell metabolism 2022; (34(7)):947-968 doi:10.1016/j.cmet.2022.06.003.
PMID: 35728586 - 6
Mitochondrial Dysfunction and Mitophagy in Type 2 Diabetes: Pathophysiology and Therapeutic Targets.
Apostolova N, Vezza T, Muntane J, et al.
Antioxidants & redox signaling 2023; (39(4-6)):278-320 doi:10.1089/ars.2022.0016.
PMID: 36641637 - 7
Diabetes Associated With Maternally Inherited Diabetes and Deafness (MIDD): From Pathogenic Variant to Phenotype.
Chanoine JP, Thompson DM, Lehman A
Diabetes 2025; (74(2)):153-163 doi:10.2337/db24-0515.
PMID: 39556456 - 8
Metabolic remodeling in hiPSC-derived myofibers carrying the m.3243A>G mutation.
Valdebenito GE, Chacko AR, Chung CY, et al.
Stem cell reports 2025; (20(4)):102448 doi:10.1016/j.stemcr.2025.102448.
PMID: 40086445 - 9
Pathogenic mitochondrial DNA 3243A>G mutation: From genetics to phenotype.
Li D, Liang C, Zhang T, et al.
Frontiers in genetics 2022; (13()):951185 doi:10.3389/fgene.2022.951185.
PMID: 36276941 - 10
Two sisters with macular dystrophy caused by the 3243A>G mitochondrial DNA mutation.
Sánchez-Gutiérrez V, García-Montesinos J, Pardo-Muñoz A
Archivos de la Sociedad Espanola de Oftalmologia 2016; (91(5)):240-4.
PMID: 26897329 - 11
The first concurrent detection of mitochondrial DNA m.3243A>G mutation, deletion, and depletion in a family with mitochondrial diabetes.
Tabebi M, Safi W, Felhi R, et al.
Molecular genetics & genomic medicine 2020; (8(7)):e1292 doi:10.1002/mgg3.1292.
PMID: 32394641 - 12
Phenotypic Heterogeneity in 5 Family Members with the Mitochondrial Variant m.3243A>G.
Finsterer J, Laccone F
The American journal of case reports 2020; (21()):e927938 doi:10.12659/AJCR.927938.
PMID: 33237887 - 13
Clinical Characteristics of Diabetes in People with Mitochondrial DNA 3243A>G Mutation in Korea.
Rho EH, Baek SI, Lee H, et al.
Diabetes & metabolism journal 2024; (48(3)):482-486 doi:10.4093/dmj.2023.0078.
PMID: 38311059 - 14
Heteroplasmy and phenotype spectrum of the mitochondrial tRNALeu (UUR) gene m.3243A>G mutation in seven Han Chinese families.
Liu G, Shen X, Sun Y, et al.
Journal of the neurological sciences 2020; (408()):116562 doi:10.1016/j.jns.2019.116562.
PMID: 31722256 - 15
Phenotypic heterogeneity in m.3243A>G mitochondrial disease: The role of nuclear factors.
Pickett SJ, Grady JP, Ng YS, et al.
Annals of clinical and translational neurology 2018; (5(3)):333-345 doi:10.1002/acn3.532.
PMID: 29560378 - 16
Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes diagnosed after metformin-triggered stroke-like episodes.
Murakami K, Sakamoto K, Ishiguchi H, Ito H
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2023; (32(5)):107080 doi:10.1016/j.jstrokecerebrovasdis.2023.107080.
PMID: 36933522 - 17
Mitochondrial Disorder: Maternally Inherited Diabetes and Deafness.
Tsang SH, Aycinena ARP, Sharma T
Advances in experimental medicine and biology 2018; (1085()):163-165 doi:10.1007/978-3-319-95046-4_31.
PMID: 30578504 - 18
Mitochondrial heteroplasmy-phenotype correlation and response to glucose lowering therapy in subjects with m.3243A>G mutations.
Ng N, Sanchez-Lechuga B, McCarrick CJ, et al.
Diabetes & metabolism 2025; (51(5)):101678 doi:10.1016/j.diabet.2025.101678.
PMID: 40541739 - 19
Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm.
Chaudhry A, Thompson DM, Chanoine JP
Diabetes, obesity & metabolism 2025; doi:10.1111/dom.70240.
PMID: 41145374 - 20
Management of mitochondrial diabetes in the era of novel therapies.
Yeung RO, Al Jundi M, Gubbi S, et al.
Journal of diabetes and its complications 2021; (35(1)):107584 doi:10.1016/j.jdiacomp.2020.107584.
PMID: 32331977 - 21
Mitochondrial Macular Dystrophy-A Case Report and Mini Review of Retinal Dystrophies.
Rotuski G, Paczwa K, Mędrzycka J, et al.
Journal of clinical medicine 2025; (14(22)) doi:10.3390/jcm14228236.
PMID: 41303269
This page explains the connection between MELAS syndrome and diabetes for educational purposes. Always consult your endocrinologist or mitochondrial disease specialist before changing your diet or diabetes medication.
Get notified when new evidence is published on MELAS.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.